Oncternal Therapeutics announced the approval of an inducement award to one new employee, Rebecca Nolan-Olson, who is joining Oncternal as Safety Manager. The award will be made on January 2, 2024 under Oncternal’s 2021 Employment Inducement Incentive Award Plan, which provides for the granting of equity awards to new employees of Oncternal as an inducement to join the Company. The award will consist of an option to purchase 19,500 shares of Oncternal common stock. The option will have a 10-year term and an exercise price equal to the closing price of Oncternal’s common stock on the date of grant. The option will vest over a four-year period, with 25% of the shares subject to the option vesting on the first anniversary of the employee’s start date, and the rest vesting in equal monthly installments over three years thereafter. The award was approved by Oncternal’s compensation committee, comprised entirely of independent directors, as required by Nasdaq Rule 5635(c)(4), and will be granted as an inducement material to the employee entering into employment with Oncternal in accordance with Nasdaq Rule 5635(c)(4).
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ONCT:
- Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
- Oncternal Therapeutics Updates the Status of its Phase 1/2 Study of ONCT-808, a ROR1-Targeting Autologous CAR T, in Patients with Relapsed or Refractory Aggressive B-cell Lymphoma
- Oncternal Therapeutics provides update on Phase 1/2 study of lymphoma candidate
- Oncternal Therapeutics upgraded to Buy from Hold at Brookline
- Oncternal Therapeutics Provides Business Update and Announces Third Quarter 2023 Financial Results